Given the previously postulated, we can deduce that carriers of PON1 polymorphisms known to lead to augmented enzyme levels and activity, may have lower susceptibility to oxidation and inflammation, thus lowering the incidence of accelerated atherosclerosis and CVD, and vice versa. The gene discussed is PON1; the disease is atherosclerosis.